Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Effects of Atomoxetine on Cognitive Function in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia
Cognition
Smoking

First Posted Date: 2007-01-11

Last Posted Date: 2007-12-12

Lead Sponsor: Yale University

Target Recruit Count: 12

Registration Number: NCT00420498

Locations: 🇺🇸
Connecticut Mental Health Center, SAC-115, New Haven, Connecticut, United States

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

Phase 3

Completed

Conditions: Hypophosphatemia, Familial
Hyperparathyroidism

Interventions: Drug: Paricalcitol
Other: Placebo

First Posted Date: 2007-01-01

Last Posted Date: 2020-03-17

Lead Sponsor: Yale University

Target Recruit Count: 33

Registration Number: NCT00417612

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Craving, Binge Eating and Obesity

Phase 2

Completed

Conditions: Binge Eating Disorder
Obesity

Interventions: Other: Placebo
Drug: bupropion

First Posted Date: 2006-12-21

Last Posted Date: 2020-04-03

Lead Sponsor: Yale University

Target Recruit Count: 61

Registration Number: NCT00414167

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Not Applicable

Completed

Conditions: Impaired Glucose Tolerance
Type 2 Diabetes Mellitus
Obesity

Interventions: Drug: Rosiglitazone
Drug: Placebo

First Posted Date: 2006-12-19

Last Posted Date: 2013-07-22

Lead Sponsor: Yale University

Target Recruit Count: 21

Registration Number: NCT00413335

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Capecitabine
Drug: PHY906

First Posted Date: 2006-12-15

Last Posted Date: 2015-03-27

Lead Sponsor: Yale University

Target Recruit Count: 25

Registration Number: NCT00411762

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Rapamycin
Drug: Trastuzumab

First Posted Date: 2006-12-15

Last Posted Date: 2016-09-21

Lead Sponsor: Yale University

Target Recruit Count: 11

Registration Number: NCT00411788

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Bridgeport Hospital, Bridgeport, Connecticut, United States

Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children

Not Applicable

Completed

Conditions: Pediatric Obesity
Insulin Resistance
Hyperinsulinemia

First Posted Date: 2006-12-08

Last Posted Date: 2008-06-24

Lead Sponsor: Yale University

Target Recruit Count: 200

Registration Number: NCT00409422

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Brief Introductory Therapy for Opioid Dependence

Phase 2

Completed

Conditions: Opiate Dependence
HIV Infections

Interventions: Behavioral: BDRC
Behavioral: Standard drug counseling

First Posted Date: 2006-12-04

Last Posted Date: 2020-04-02

Lead Sponsor: Yale University

Target Recruit Count: 51

Registration Number: NCT00406484

Locations: 🇺🇸
Methadone Research Unit, The APT Foundation, Inc., New Haven, Connecticut, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma

First Posted Date: 2006-11-22

Last Posted Date: 2013-12-18

Lead Sponsor: Yale University

Target Recruit Count: 3

Registration Number: NCT00402662

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy

Phase 1

Terminated

Conditions: Tumors

Interventions: Drug: Sunitinib malate
Drug: Rapamycin

First Posted Date: 2006-11-22

Last Posted Date: 2013-12-18

Lead Sponsor: Yale University

Target Recruit Count: 18

Registration Number: NCT00402415

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy